Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Summary
Third Opinion Trial Synopsis:
This study is testing if a medicine called Isatuximab can help people with certain types of cancer. The medicine might change their immune system to help fight the cancer. The study will have two groups of people - one group will get the normal cancer treatment, and the other group will get the normal treatment plus the medicine. The group each person is in is chosen randomly. It's like flipping a coin. Each person has a higher chance of getting the medicine group.
This study is testing if a medicine called Isatuximab can help people with certain types of cancer. The medicine might change their immune system to help fight the cancer. The study will have two groups of people - one group will get the normal cancer treatment, and the other group will get the normal treatment plus the medicine. The group each person is in is chosen randomly. It's like flipping a coin. Each person has a higher chance of getting the medicine group.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), participants will receive Isatuximab in addition to the standard transplant procedures. The assignment to these arms is done randomly (determined by chance, like flipping a coin) by a computer. Each participant will have about 66% chance of getting on the experimental arm and about 33% chance of getting on the control arm.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: